PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide
- Design
- Cell / in-vitro
- Drugs
- Tirzepatide
- Assessment
- Not yet reviewed by a person · added Nov 8, 2026
This study was added automatically and has not been reviewed. Until it is, the collection publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.
01Source
The source, as retrieved
Abstract
Tirzepatide is a clinical dual GLP-1R and GIPR agonist for type 2 diabetes and obesity, and non-invasive approaches to assess its in vivo biodistribution and systemic toxicity in living animals remain limited. Both receptors also serve as potential targets for neuroendocrine tumor imaging, and dual-target PET probes for simultaneous GLP-1R and GIPR detection are still lacking. Herein, we developed a novel PET probe [18F]AlF-NOTA-Asp2-tirzepatide via structural modification of tirzepatide. This probe successfully visualized the in vivo distribution of tirzepatide, which was primarily eliminated through the renal system. The C20 fatty diacid moiety caused elevated uptake in the heart, liver and blood due to enhanced albumin binding. In vitro assays verified its reliable GLP-1R and moderate GIPR binding affinity. Persistent tumor accumulation was observed in INS-1 and A549-GIPR xenografts, allowing effective tumor visualization. In summary, [18F]AlF-NOTA-Asp2-tirzepatide features facile radiolabeling and enables the clear visualization of tirzepatide in vivo, along with favorable dual-targeting performance, while excessive non-target uptake still needs to be optimized for further clinical translation.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Nov 8, 2026 | 42969740 first ingestion |